JACC-HF Reports Successful Heart Failure Trial With Daxor BVA-100®

Researchers Call for Larger Clinical Trial Citing Outcomes from Study

Oak Ridge, TN, Aug. 10, 2023 (GLOBE NEWSWIRE) — Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces a research letter in the Journal of the American College of Cardiology – Heart Failure reporting on the successful results of a pilot 31 patient randomized control trial (RCT) conducted by the Duke Clinical Research Institute utilizing Daxor’s BVA-100 diagnostic to measure clinician assessment accuracy and the impact of optimizing decongestion therapy for heart failure patients with the diagnostic.

The study results showed that all patients had marked volume derangements, but that in over 68% of the cases care teams did not correctly diagnose the volume state of the patient by clinical exam when compared to BVA. Marat Fudim, M.D., principal investigator concluded, “Physician judgment of congestion status is not an accurate representation of actual blood volume. Our findings support the feasibility of randomized trials of BVA-guided heart failure therapy and our encouraging findings support a future, large, multicenter RCT to further investigate the effect of BVA measurement clinical outcomes.”

The study showed that utilizing the BVA-100 early in patient admission in the setting of a heart failure RCT was practical, but that optimization of the process would be part of a larger study trial design. Other measured outcomes such as patients in the control group being treated more effectively to an optimal volume, and being discharged after shorter lengths of stay were noted by researchers, but the findings did not reach statistical significance due to the small sample size of the study population.

“This pilot RCT provides further evidence that Daxor’s technology is a practical and effective solution to the challenge of optimizing heart failure care,” said Michael Feldschuh, Daxor’s CEO and President. “This first-of-its-kind RCT adds further validation to existing clinical use of our diagnostic in heart failure and confirms that surrogate markers such a physical exam are not accurate or precise compared to direct and objective measurement with Daxor’s BVA system. Daxor will continue to work toward larger randomized trials building on the evidence published by these and other researchers.”

Link to Research Letter HERE.

About Daxor Corporation

Daxor Corporation (NASDAQ: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100^® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor’s mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com